Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Associations between metabolic hyperferritinaemia, fibrosis-promoting alleles and clinical outcomes in steatotic liver disease.

Liver international : official journal of the International Association for the Study of the Liver - 1 Feb 2024

Suresh Deepika, Li Ashley, Miller Matthew J, Wijarnpreecha Karn, Chen Vincent L

Abstract excerpt

BACKGROUND & AIMS: Ferritin has been investigated as a biomarker for liver fibrosis and iron in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). However, whether metabolic hyperferritinaemia predicts progression of liver disease remains unknown. In this study, we sought to understand associations between hyperferritinaemia and (1) adverse clinical outcomes and (2) common genetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Fatty Liver

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ferritins

Share to Fibrosis

Share to Hemochromatosis

Share to Liver Cirrhosis

Source

Open in PubMed Open full text

Identifiers

PMID: 37971775
DOI: 10.1111/liv.15787
PMCID: PMC10872664

Genes

HFE
PNPLA3
TM6SF2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Associations between metabolic hyperferritinaemia, fibrosis-promoting alleles and clinical outcomes in steatotic liver disease.PMID 37971775Read ↗

Clinical Setting Modulates the Association Between Genetic Variants and Fibrosis Severity Across the Spectrum of MASLD.Semantic proximity Read ↗

Polymorphisms Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease Influence the Progression of End-Stage Liver DiseaseSemantic proximity Read ↗

Epidemiological and transcriptome data identify association between iron overload and metabolic dysfunction-associated steatotic liver disease and hepatic fibrosisSemantic proximity Read ↗

Serum ferritin level is associated with liver fibrosis and incident liver-related outcomes independent of HFE genotype in the general population.Semantic proximity Read ↗

Hyperferritinemia is a risk factor for steatosis in chronic liver disease.Semantic proximity Read ↗

GCKR genetic variants and circulating FGF21 define a metabolic risk signature in Metabolic-associated Steatotic Liver diseaseSemantic proximity Read ↗

Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).Semantic proximity Read ↗

Alpha 1-antitrypsin mutations in NAFLD: high prevalence and association with altered iron metabolism but not with liver damage.Semantic proximity Read ↗

Liver fibrosis assessed using non-invasive markers and genetic polymorphisms (<i>PNPLA3</i>and<i>TM6SF2</i>) predisposing to liver fibrosis, is associated with hospitalization or death from heart failure: a prospective UK Biobank studySemantic proximity Read ↗

High inherited risk predicts age-associated increases in fibrosis in patients with MASLD.Semantic proximity Read ↗

Differential Effects of Genetic Polymorphism on Comorbid Disease in Metabolic Dysfunction-Associated Steatotic Liver Disease.Semantic proximity Read ↗

Clinical Utility of Genetic Variants in PNPLA3 and TM6SF2 to Predict Liver-Related Events in Metabolic Dysfunction-Associated Steatotic Liver Disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.